John C. Davis

20.0k total citations · 6 hit papers
216 papers, 10.9k citations indexed

About

John C. Davis is a scholar working on Rheumatology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John C. Davis has authored 216 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Rheumatology, 37 papers in Hematology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John C. Davis's work include Spondyloarthritis Studies and Treatments (45 papers), Rheumatoid Arthritis Research and Therapies (39 papers) and Autoimmune and Inflammatory Disorders Research (25 papers). John C. Davis is often cited by papers focused on Spondyloarthritis Studies and Treatments (45 papers), Rheumatoid Arthritis Research and Therapies (39 papers) and Autoimmune and Inflammatory Disorders Research (25 papers). John C. Davis collaborates with scholars based in United States, United Kingdom and Netherlands. John C. Davis's co-authors include Désirée van der Heijde, Jürgen Braun, Joachim Sieper, Jennifer D. Gorman, Kenneth E. Sack, John D. Reveille, Maxime Dougados, Robert Landewé, S van der Linden and H. L. Sheehan and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

John C. Davis

211 papers receiving 10.3k citations

Hit Papers

Development of an ASAS-endorsed disease activity score (A... 2002 2026 2010 2018 2008 2006 2003 2002 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
    2008 720 citations Robert Landewé, Joachim Sieper et al. Annals of the Rheumatic Diseases profile →
  2. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
    2006 660 citations Désirée van der Heijde, Michael Schiff et al. Arthritis & Rheumatism profile →
  3. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
    2003 583 citations John C. Davis, Désirée van der Heijde et al. Arthritis & Rheumatism profile →
  4. Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
    2002 551 citations Jennifer D. Gorman, John C. Davis et al. profile →
  5. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial
    2008 444 citations John C. Davis, Désirée van der Heijde et al. Arthritis & Rheumatism profile →
  6. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept
    2008 408 citations Robert Landewé, John C. Davis et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John C. Davis United States 50 7.0k 4.1k 2.3k 1.8k 1.2k 216 10.9k
D Alarcón-Segovia Mexico 56 7.3k 1.0× 4.4k 1.1× 1.7k 0.7× 940 0.5× 1.1k 1.0× 342 12.3k
Ricardo Blanco Spain 49 6.0k 0.9× 2.7k 0.7× 1.8k 0.8× 2.9k 1.7× 1.3k 1.2× 461 10.1k
Tsuneyo Mimori Japan 59 6.0k 0.9× 3.2k 0.8× 847 0.4× 1.8k 1.0× 3.2k 2.8× 396 12.9k
Graham R.V. Hughes United Kingdom 68 13.6k 1.9× 4.4k 1.1× 4.3k 1.9× 2.7k 1.6× 1.2k 1.0× 263 18.2k
Pierre Miossec France 65 6.1k 0.9× 9.3k 2.3× 2.5k 1.1× 701 0.4× 3.5k 3.0× 304 18.6k
Andrea Doria Italy 75 10.3k 1.5× 7.0k 1.7× 1.6k 0.7× 1.2k 0.7× 2.4k 2.1× 515 17.9k
Matthias Schneider Germany 41 5.0k 0.7× 2.2k 0.5× 1.5k 0.7× 581 0.3× 689 0.6× 398 8.1k
Naomi F. Rothfield United States 48 12.7k 1.8× 7.8k 1.9× 1.5k 0.7× 1.4k 0.8× 2.7k 2.4× 125 19.8k
Stefano Bombardieri Italy 65 6.4k 0.9× 5.1k 1.2× 1.2k 0.5× 1.5k 0.9× 2.2k 1.9× 448 16.2k
Manabu Fujimoto Japan 68 3.3k 0.5× 6.8k 1.6× 686 0.3× 2.4k 1.4× 3.3k 2.9× 486 17.7k

Countries citing papers authored by John C. Davis

Since Specialization
Citations

This map shows the geographic impact of John C. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Davis more than expected).

Fields of papers citing papers by John C. Davis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Davis. The network helps show where John C. Davis may publish in the future.

Co-authorship network of co-authors of John C. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Davis. A scholar is included among the top collaborators of John C. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Davis. John C. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ward, Michael M., Thomas J. Learch, Lianne S. Gensler, et al.. (2012). Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: Differences in early and late disease. Arthritis Care & Research. 65(2). 257–265. 24 indexed citations
2.
Tómasson, Gunnar, Michael P. LaValley, Kahraman Tanrıverdi, et al.. (2011). Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener’s Granulomatosis. The Journal of Rheumatology. 38(6). 1048–1054. 39 indexed citations
3.
Tómasson, Gunnar, Maarten Boers, Michael Walsh, et al.. (2011). Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care & Research. 64(2). 273–279. 48 indexed citations
4.
Zheng, Yanan, Heleen Scheerens, John C. Davis, et al.. (2010). Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study. Clinical Pharmacology & Therapeutics. 89(2). 283–290. 34 indexed citations
5.
Ward, Michael M., James D. Malley, Thomas J. Learch, et al.. (2009). Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Care & Research. 61(7). 859–866. 97 indexed citations
6.
Dougados, Maxime, Michelle P. Luo, Walter P. Maksymowych, et al.. (2008). Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: Data from a randomized controlled trial. Arthritis Care & Research. 59(4). 553–560. 33 indexed citations
7.
Reveille, John D., L Bradbury, John C. Davis, et al.. (2007). Il-23r is a major determinant of ankylosing spondylitis risk - The tasc study. Annals of the Rheumatic Diseases. 66. 112–112. 7 indexed citations
8.
Braun, Jürgen, Xenofon Baraliakos, Joachim Listing, et al.. (2007). Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents. Arthritis Care & Research. 57(4). 639–647. 145 indexed citations
9.
Heijde, Désirée van der, Aileen L. Pangan, Michael Schiff, et al.. (2007). Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Annals of the Rheumatic Diseases. 67(9). 1218–1221. 47 indexed citations
10.
Davis, John C., et al.. (2006). Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis. Nature Clinical Practice Rheumatology. 2(4). 211–218. 20 indexed citations
11.
Davis, John C., Désirée van der Heijde, Maxime Dougados, & J. Michael Woolley. (2005). Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis & Rheumatism. 53(4). 494–501. 89 indexed citations
12.
Emery, Paul, Lars Klareskog, John C. Davis, & René Westhovens. (2005). Selective Costimulation Modulators: Addressing Unmet Needs in Rheumatoid Arthritis Management. PubMed Central. 6(1). 53–5. 2 indexed citations
13.
Seo, Philip, Yuan‐I Min, Janet T. Holbrook, et al.. (2005). Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis & Rheumatism. 52(7). 2168–2178. 140 indexed citations
14.
Merkel, Peter A., Janet T. Holbrook, Nancy B. Allen, et al.. (2005). Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Annals of Internal Medicine. 142(8). 620–620. 10 indexed citations
15.
Wanders, Astrid J. B., Jennifer D. Gorman, John C. Davis, Robert Landewé, & Désirée van der Heijde. (2004). Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease‐controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Care & Research. 51(1). 1–8. 41 indexed citations
16.
Stone, John H., Gary S. Hoffman, Peter A. Merkel, et al.. (2001). A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis & Rheumatism. 44(4). 912–920. 352 indexed citations
17.
Casson, I. F., John C. Davis, R. V. Jeffreys, et al.. (1987). SUCCESSFUL MANAGEMENT OF CUSHING'S DISEASE DURING PREGNANCY BY TRANSSPHENOIDAL ADENECTOMY. Clinical Endocrinology. 27(4). 423–428. 38 indexed citations
18.
Davis, John C. & W. J. Tango. (1979). High angular resolution stellar interferometry : proceedings of Colloquium no.50 IAU, held at The University of maryland, College Park, Maryland, U.S.A., 30 August - 1 September, 1978. 7 indexed citations
19.
Summers, V. K., et al.. (1966). HYPERPARATHYROIDISM IN ACROMEGALY Findings in Three Cases. The Lancet. 288(7464). 601–604. 8 indexed citations
20.
Davis, John C., et al.. (1962). CARCINOMA OF BRONCHUS AND CUSHING'S SYNDROME. The Lancet. 280(7255). 534–536. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D Alarcón-Segovia Breakdown of academic impact, for papers by Ricardo Blanco Breakdown of academic impact, for papers by Tsuneyo Mimori Breakdown of academic impact, for papers by Graham R.V. Hughes Breakdown of academic impact, for papers by Pierre Miossec Breakdown of academic impact, for papers by Andrea Doria Breakdown of academic impact, for papers by Matthias Schneider Breakdown of academic impact, for papers by Naomi F. Rothfield Breakdown of academic impact, for papers by Stefano Bombardieri Breakdown of academic impact, for papers by Manabu Fujimoto
Rankless by CCL
2026